Beamr video compression achieves up to 50% improvement for AVs
Investing.com - Alaunos Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Alaunos Therapeutics announced earnings per share of $-0.040 on revenue of $2.9M. Analysts polled by Investing.com EPS of $-0.050 on revenue of $0.
Alaunos Therapeutics 's are down 22% and is trading at $1.080 , still down 73.07% from its 52 week high of $4.01 set on Friday, September 9, 2022.
Alaunos Therapeutics follows other major Healthcare sector earnings this month
Alaunos Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar